Opening book details…
Can I read RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid on EtoBox?
RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid by Todd M. Morgan; Tiffany E.M. Pitts; Ted S. Gross; Sandra L. Poliachik; Robert L. Vessella; Eva Corey is a Medicine article available to read on EtoBox.
What is RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid about?
## Abstract ## Introduction mTOR activity is increased in advanced prostate cancer (CaP) as a result of a high rate of PTEN mutations. RAD001 (Everolimus) is a new orally available mTOR inhibitor. The objective of our study was to evaluate the effects of RAD001 on the growth of CaP in the bone, both alone and in combination with docetaxel and zoledronic acid. ## Methods C4‐2 CaP cells were injected into tibiae of mice and the animals were treated with RAD001, docetaxel, and zoledronic acid alone or in combination. Histomorphometrical analysis, serum PSA measurements, bone mineral density (BMD), and μCT were used to determine the effects of treatment on tumor and bone. ## Results All three agents alone decreased tumor volume, and RAD001 and docetaxel also decreased levels of serum PSA by 68% and 65%, respectively (both __P__ < 0.01). Combinations of the agents were more effective in decreasing tumor volume than single agents. Three‐drug treatment showed the greatest effect: 64% inhibition versus control (__P__ < 0.01). Treatment with RAD001 interfered with the weight loss associated with growth of this tumor in the bone (non‐RAD001 groups: 4.0% decrease in body weight, __P__ = 0.001
Who reads RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Todd M. Morgan; Tiffany E.M. Pitts; Ted S. Gross; Sandra L. Poliachik; Robert L. Vessella; Eva Corey
- Publisher
- John Wiley and Sons; Wiley (John Wiley & Sons); John Wiley & Sons Inc.; Wiley (ISSN 0270-4137)
- Published
- 2008
- Language
- EN
- Field
- Medicine (Health Sciences)